The Case for a New Generation of Oral Therapies in Inflammatory Bowel Disease - Back Bay Life Science Advisors and Nimbus Therapeutics

Despite advances in the treatment of inflammatory bowel disease (IBD), many patients with moderate-to-severe ulcerative colitis (UC) and Crohn’s disease continue to experience inadequate disease control with available biologics and targeted therapies. IBD is a chronic disease often diagnosed in young adults, and many patients cycle through multiple therapies due to loss of response, tolerability concerns, or incomplete disease control. There remains a clear need for treatments that deliver deeper, more durable remission with less long-term burden. 

Back Bay Life Science Advisors teamed up with Nimbus Therapeutics for a look at the IBD space. Learn more about Nimbus on their website.

CONTRIBUTING AUTHORS

Christian Thienel, Director, Back Bay Life Science Advisors
Leah Strickling, Director, Corporate Development & Strategy, Nimbus Therapeutics
Leon Collis, Executive Director, Biology, Nimbus Therapeutics
Cindy Fung, PhD, VP, Corporate Affairs & Communications, Nimbus Therapeutics
Peter Bak, PhD, Managing Director, Back Bay Life Science Advisors